Prakash Ramachandran

List of Publications by Year
in descending order

39 papers	5,709 citations	304743 22 h-index	361022 35 g-index
45 all docs	45 docs citations	45 times ranked	8852 citing authors

#	Article	IF	Citations
1	Deciphering Mesenchymal Drivers of Human Dupuytrenâ€™s Disease at Single-Cell Level. Journal of Investigative Dermatology, 2022, 142, 114-123.e8.	0.7	12
2	Genomeâ€Wide Association Study of NAFLD Using Electronic Health Records. Hepatology Communications, 2022, 6, 297-308.	4.3	33
3	Genomeâ€wide analysis identifies gallstoneâ€susceptibility loci including genes regulating gastrointestinal motility. Hepatology, 2022, 75, 1081-1094.	7.3	12
4	Macrophages as key regulators of liver health and disease. International Review of Cell and Molecular Biology, 2022, , 143-212.	3.2	18
5	A relaxin-based nanotherapy for liver fibrosis. Nature Nanotechnology, 2021, 16, 365-366.	31.5	8
6	Role of Tim4 in the regulation of ABCA1+ adipose tissue macrophages and post-prandial cholesterol levels. Nature Communications, 2021, 12, 4434.	12.8	27
7	CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease. Nature Communications, 2021, 12, 7172.	12.8	22
8	Kidney Single-Cell Atlas Reveals Myeloid Heterogeneity in Progression and Regression of Kidney Disease. Journal of the American Society of Nephrology: JASN, 2020, 31, 2833-2854.	6.1	113
9	Single-cell RNA-seq reveals CD16- monocytes as key regulators of human monocyte transcriptional response to Toxoplasma. Scientific Reports, 2020, 10, 21047.	3.3	8
10	Single-cell technologies in hepatology: new insights into liver biology and disease pathogenesis. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 457-472.	17.8	152
11	Single-cell analyses and machine learning define hematopoietic progenitor and HSC-like cells derived from human PSCs. Blood, 2020, 136, 2893-2904.	1.4	44
12	Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature, 2019, 575, 512-518.	27.8	946
13	Single-Cell Transcriptomics Uncovers Zonation of Function in the Mesenchyme during Liver Fibrosis. Cell Reports, 2019, 29, 1832-1847.e8.	6.4	261
14	Single Cell Sequencing Reveals Heterogeneity Of Adventitial Mesenchymal Cells In Healthy Mice. Atherosclerosis, 2019, 287, e49.	0.8	0
15	11Betaâ€hydroxysteroid dehydrogenaseâ€1 deficiency or inhibition enhances hepatic myofibroblast activation in murine liver fibrosis. Hepatology, 2018, 67, 2167-2181.	7.3	21
16	Studies of macrophage therapy for cirrhosis â€“ From mice to men. Journal of Hepatology, 2018, 68, 1090-1091.	3.7	3
17	Immune cell regulation of liver regeneration and repair. Journal of Immunology and Regenerative Medicine, 2018, 2, 1-10.	0.4	13
18	Sphingosine-1-Phosphate Prevents Egress of Hematopoietic Stem Cells From Liver to Reduce Fibrosis. Gastroenterology, 2017, 153, 233-248.e16.	1.3	48

#	Article	IF	Citations
19	Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial. PLoS Medicine, 2017, 14, e1002248.	8.4	45
20	Antifibrotics in chronic liver disease: tractable targets and translational challenges. The Lancet Gastroenterology and Hepatology, 2016, 1, 328-340.	8.1	36
21	Resolution of Liver Fibrosis: Basic Mechanisms and Clinical Relevance. Seminars in Liver Disease, 2015, 35, 119-131.	3.6	96
22	Decompensated liver cirrhosis. Anaesthesia and Intensive Care Medicine, 2015, 16, 180-185.	0.2	2
23	Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nature Reviews Immunology, 2014, 14, 181-194.	22.7	1,054
24	PWE-136â€...Hepatocellular Cancer Detected In The Cirrhosis Surveillance Programme Have Better Outcomes Than Those Diagnosed Symptomatically. Gut, 2014, 63, A184.2-A184.	12.1	1
25	PWE-146â€...Relaxinâ€...Is a Renal Vasodilator in Experimental Models of Cirrhosis and A Potential Novel Therapy for Hepatorenal Syndrome in Humans. Gut, 2013, 62, A190.3-A191.	12.1	0
26	Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3186-95.	7.1	793
27	Focusing on the patient: impact of new UK guidelines on treatment of chronic hepatitis C. Expert Review of Gastroenterology and Hepatology, 2012, 6, 259-261.	3.0	0
28	Liver fibrosis: a bidirectional model of fibrogenesis and resolution. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 813-817.	0.5	87
29	<scp>UK</scp> consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis <scp>C</scp> infected patients. Alimentary Pharmacology and Therapeutics, 2012, 35, 647-662.	3.7	76
30	Macrophages: Central regulators of hepatic fibrogenesis and fibrosis resolution. Journal of Hepatology, 2012, 56, 1417-1419.	3.7	94
31	Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nature Medicine, 2012, 18, 572-579.	30.7	624
32	Elastin accumulation is regulated at the level of degradation by macrophage metalloelastase (MMP-12) during experimental liver fibrosis. Hepatology, 2012, 55, 1965-1975.	7.3	158
33	Reversibility of liver fibrosis. Fibrogenesis and Tissue Repair, 2012, 5, S26.	3.4	88
34	Stem Cell Therapy in the Context of Chronic Liver Disease. , 2012, , 1-6.		0
35	Ly6C^{hi}Monocytes Direct Alternatively Activated Profibrotic Macrophage Regulation of Lung Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 569-581.	5.6	383
36	Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function. Hepatology, 2011, 53, 2003-2015.	7.3	278

#	Article	IF	Citations
37	Reversibility of liver fibrosis. Annals of Hepatology, 2009, 8, 283-291.	1.5	88
38	Reversibility of liver fibrosis. Annals of Hepatology, 2009, 8, 283-91.	1.5	42
39	Liver fibrosis and repair: immune regulation of wound healing in a solid organ. , 0, .		1